These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

507 related items for PubMed ID: 26783352

  • 1. Meta-analysis of the Efficacy and Safety of Secukinumab for the Treatment of Plaque Psoriasis.
    Ryoo JY, Yang HJ, Ji E, Yoo BK.
    Ann Pharmacother; 2016 May; 50(5):341-51. PubMed ID: 26783352
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and Safety of Secukinumab for the Treatment of Psoriasis: A Meta-Analysis of Pivotal Phase III Trials.
    Zhou Y, Zhang K, Ma X, Xie Z.
    Dermatology; 2024 May; 240(2):271-281. PubMed ID: 37926074
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.
    van de Kerkhof PC, Griffiths CE, Reich K, Leonardi CL, Blauvelt A, Tsai TF, Gong Y, Huang J, Papavassilis C, Fox T.
    J Am Acad Dermatol; 2016 Jul; 75(1):83-98.e4. PubMed ID: 27180926
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Secukinumab efficacy and safety in indian patients with moderate-to-severe plaque psoriasis: Sub-analysis from FIXTURE, a randomized, placebo-controlled, phase 3 study.
    Bhat RM, Leelavathy B, Aradhya SS, Gopal MG, Pratap DV, Mubashir M, Srinivas P, Pande SY, Thavkar AS.
    Indian Dermatol Online J; 2017 Jul; 8(1):16-24. PubMed ID: 28217466
    [Abstract] [Full Text] [Related]

  • 9. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).
    Paul C, Lacour JP, Tedremets L, Kreutzer K, Jazayeri S, Adams S, Guindon C, You R, Papavassilis C, JUNCTURE study group.
    J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1082-90. PubMed ID: 25243910
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies.
    Körber A, Papavassilis C, Bhosekar V, Reinhardt M.
    Drugs Aging; 2018 Feb; 35(2):135-144. PubMed ID: 29404966
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
    Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, Haemmerle S, Thurston HJ, Papavassilis C, Richards HB.
    Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: Subanalysis from ERASURE phase III study.
    Wu NL, Hsu CJ, Sun FJ, Tsai TF.
    J Dermatol; 2017 Oct; 44(10):1129-1137. PubMed ID: 28493369
    [Abstract] [Full Text] [Related]

  • 14. Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials.
    Adsit S, Zaldivar ER, Sofen H, Dei-Cas I, Maldonado-García C, Peñaranda EO, Puig L, Meng X, Fox T, Guana A.
    Adv Ther; 2017 Jun; 34(6):1327-1339. PubMed ID: 28397079
    [Abstract] [Full Text] [Related]

  • 15. Secukinumab Self-Administration by Prefilled Syringe Maintains Reduction of Plaque Psoriasis Severity Over 52 Weeks: Results of the FEATURE Trial.
    Gottlieb AB, Blauvelt A, Prinz JC, Papanastasiou P, Pathan R, Nyirady J, Fox T, Papavassilis C.
    J Drugs Dermatol; 2016 Oct 01; 15(10):1226-1234. PubMed ID: 27741340
    [Abstract] [Full Text] [Related]

  • 16. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
    Thaçi D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, Ziv M, Pinter A, Hugot S, You R, Milutinovic M.
    J Am Acad Dermatol; 2015 Sep 01; 73(3):400-9. PubMed ID: 26092291
    [Abstract] [Full Text] [Related]

  • 17. Secukinumab: a review in moderate to severe plaque psoriasis.
    Garnock-Jones KP.
    Am J Clin Dermatol; 2015 Aug 01; 16(4):323-330. PubMed ID: 26202871
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study.
    Imafuku S, Honma M, Okubo Y, Komine M, Ohtsuki M, Morita A, Seko N, Kawashima N, Ito S, Shima T, Nakagawa H.
    J Dermatol; 2016 Sep 01; 43(9):1011-7. PubMed ID: 26919410
    [Abstract] [Full Text] [Related]

  • 19. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).
    Blauvelt A, Prinz JC, Gottlieb AB, Kingo K, Sofen H, Ruer-Mulard M, Singh V, Pathan R, Papavassilis C, Cooper S, FEATURE Study Group.
    Br J Dermatol; 2015 Feb 01; 172(2):484-93. PubMed ID: 25132411
    [Abstract] [Full Text] [Related]

  • 20. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
    Hampton P, Halliday A, Aassi M, Subramanian S, Jain M, Griffiths CEM.
    J Eur Acad Dermatol Venereol; 2021 Apr 01; 35(4):928-937. PubMed ID: 33030755
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.